We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01135563
Recruitment Status : Completed
First Posted : June 2, 2010
Last Update Posted : September 20, 2019
Solving Kids' Cancer
Information provided by (Responsible Party):
Sylvain Baruchel, The Hospital for Sick Children

Brief Summary:
This study is a Phase I study using vinblastine and sirolimus in patients with relapsed solid tumors including selected brain tumors and lymphoma. The investigators hypothesis is that the combination administration of weekly vinblastine and sirolimus is safe.

Condition or disease Intervention/treatment Phase
Solid Tumors Central Nervous System Tumors Drug: Vinblastine and Sirolimus Phase 1

Detailed Description:
Published data demonstrating a survival advantage of the vinblastine-sirolimus regimen vs single agent in an orthopotic neuroblastoma mouse model and our unpublished data support a VBL in vitro pro-apoptotic plasma concentration of 1-2 nM range and an anti angiogenic concentration of 2pM. These plasma concentrations are achievable with a 6 mg/m2 (apoptosis) and 1 mg/m2 VBL regimen (anti-angiogenesis) weekly regimen. We expect that vinblastine delivered at any given dose, as described in the protocol, will carry both anti-apoptotic and antiangiogenic activity. Safety and preliminary efficacy of both drugs in pediatric tumors support the development of a clinical trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including CNS Tumors
Study Start Date : April 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Vinblastine and Sirolimus
The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
Drug: Vinblastine and Sirolimus

Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.

Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough

Other Names:
  • Vinblastine Sulfate Injection
  • Rapamune

Primary Outcome Measures :
  1. Maximum tolerated dose of vinblastine in combination with sirolimus [ Time Frame: 12 months ]
    Maximum tolerated dose (as defined by protocol) of vinblastine in combination with sirolimus

Secondary Outcome Measures :
  1. Safety data [ Time Frame: 12 months ]
    Safety data will be described for all patients receiving at least one dose of vinblastine and sirolimus. Safety data will include values for hematology, serum chemistry, vital signs, and adverse events. The proportion of patients experiencing adverse events, serious adverse events, dose limiting toxicities and treatment delays will be summarized for each dosing cohort.

  2. Response Rate [ Time Frame: 12 months ]
    The proportion of patients experiencing progressive disease, stable disease, partial responses or complete responses will be summarized in tabular format. Progression free survival and duration of any responses will also be summarized.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: 0-21 years at the time of diagnosis
  2. Diagnosis: Histologic verification at either the time of original diagnosis or relapse of solid tumor including CNS tumors or lymphomas
  3. Disease Status: All refractory/recurrent solid tumors including CNS tumors (all Diffuse Intrinsic Brain Stem Gliomas excluded) and lymphomas that have relapsed after, or are refractory to, a chemotherapy-containing treatment regimen
  4. Measurable disease:

    • Measurable tumor by CT or MRI defined as >10 mm by spiral CT in at least one dimension
  5. Current disease state must be one for which there is currently no known curative therapy
  6. A negative urine pregnancy test is required for female participants of child bearing potential
  7. Organ Function Requirements:

    • adequate liver function as defined by AST or ALT < 5 x upper limit of normal, bilirubin ≤1.5 X upper limit of normal
    • adequate renal function: Serum creatinine < 1.5 X upper limit of normal for age
  8. Adequate Bone Marrow Function Defined as:

    • ANC ≥ 1000/mm3, platelets ≥ 75,000/mm3 and hemoglobin ≥ 90 g/L
    • Transfusions are permitted to meet these platelet and Hgb criteria, if the patient is known to have a history of bone marrow involvement with tumor
    • Patients with platelet counts < 75,000/ mm3 who are refractory to platelet transfusions are not eligible for this study
    • Patients requiring transfusions of platelets or RBC to meet eligibility criteria will not be evaluable for platelet or hgb/hct hematological toxicity
  9. Lansky Play Score (for patients < 16 years of age) must be more than 50 and/or ECOG performance status (for patients ≥ 16 years of age) must be 0 to 2
  10. Specific requirements for Neuroblastoma patients Stratum:

    • MIBG scan with positive uptake at minimum of one site (MIBG not required if subject's neuroblastoma is previously determined to not uptake MIBG and no measurable disease)
    • Bone marrow with tumor cells seen on routine morphology (not by NSE staining only) of bilateral aspirate and /or biopsy on one bone marrow sample
  11. Written informed consent

Exclusion Criteria:

  1. Lansky score <50%
  2. Investigational Drugs: Patients who are currently receiving another investigational drug(s)
  3. Previous treatment with Vinblastine and/or mTor inhibitors
  4. Anti-cancer Agents: Patients who are currently receiving other anticancer agents. Patients must have fully recovered from the effects of prior chemotherapy, generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas)
  5. Infection: Patients who have an uncontrolled infection are not eligible until the infection is judged to be well controlled
  6. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal
  7. One week from usage of hematopoietic Growth Factor
  8. Patients who are refractory to platelet transfusions
  9. Brain Stem Glioma patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01135563

Layout table for location information
United States, California
Rady Children's Hospital-San Diego
San Diego, California, United States, 92123
United States, Missouri
SSM Cardinal Glennon Children's Medical Center
Saint Louis, Missouri, United States, 63104
United States, Vermont
Fletcher Allen Health Care
Burlington, Vermont, United States, 05401
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Canada, Quebec
CHU Sainte-Justine
Montreal, Quebec, Canada, H3T 1C5
Sponsors and Collaborators
The Hospital for Sick Children
Solving Kids' Cancer
Layout table for investigator information
Principal Investigator: Sylvain Baruchel, MD The Hospital for Sick Children, Toronto Canada
Layout table for additonal information
Responsible Party: Sylvain Baruchel, Associate Staff Oncologist, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT01135563    
Other Study ID Numbers: 1000016324
First Posted: June 2, 2010    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Keywords provided by Sylvain Baruchel, The Hospital for Sick Children:
Solid Tumors
CNS Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators